Has Jasjot Bhullar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,979 in general payments to Jasjot Bhullar, MD across 62 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jasjot Bhullar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jasjot Bhullar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jasjot Bhullar, MD

Nephrology · Loma Linda, CANPI 1366602229

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.4% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations.

$1,979in general payments, 2019–2025

Across 62 payments — averaging $31.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$404
Mallinckrodt Hospital Products Inc.$246
GSK$193
Mallinckrodt Enterprises LLC$185
Calliditas Therapeutics US Inc.$183
Baxter Healthcare$181
plus $587 from 10 others

$15,055in research payments, 2019–2025

Across 19 payments — averaging $792.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boehringer Ingelheim International GmbH$15K

What the payments were for

Food & beverage$1,86794%
Education$1126%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	25	$404
Mallinckrodt Hospital Products Inc.	2	$246
GSK	6	$193
Mallinckrodt Enterprises LLC	7	$185
Calliditas Therapeutics US Inc.	2	$183
Baxter Healthcare	2	$181
Akebia Therapeutics Inc	2	$146
Novo Nordisk	1	$111
Otsuka America Pharmaceutical, Inc.	5	$73
AstraZeneca	1	$71
Inari Medical, Inc.	1	$65
Daiichi Sankyo Inc.	3	$43
ANI Pharmaceuticals, Inc.	1	$27
OPKO Pharmaceuticals, LLC	2	$26
Fresenius USA Marketing, Inc.	1	$14
Vifor Pharma, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,979 in reported general payments places this provider in the 60th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California →

Medicare billing

Part B allowed, 2024

$65,141

Medicare patients

183

Services billed

523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JardianceEmpagliflozin	62	$43,238
Cinacalcet Hcl	12	$1,042
Omega-3 Acid Ethyl Esters	32	$811
Spironolactone	64	$411
Amlodipine Besylate	73	$345
Calcitriol	31	$324
Lisinopril	27	$302
Vitamin D2Ergocalciferol (Vitamin D2)	46	$300
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst	12	$210
Losartan Potassium	53	$202
Carvedilol	41	$183
Allopurinol	55	$164
Nifedipine ErNifedipine	15	$135
Gabapentin	14	$117
Furosemide	37	$102

Paid to pharmacies, not to this prescriber.

Other nephrology in Loma Linda

Rafael VillicanaLoma Linda$610K
Sayna NorouziLoma Linda$358K
Anjay RastogiLos Angeles$2.2M
Glenn ChertowStanford$2M
Luis AlvarezPalo Alto$1.8M
Jose MorfinSacramento$1M
Rodolfo BatarseRancho Mirage$910K
Vandana MathurWoodside$769K
Yasir QaziOrange$618K
Sunil PatelApple Valley$509K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →